The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Valecoxib     4-(5-methyl-3-phenyl-1,2- oxazol-4...

Synonyms: Bextra, Valdecoxib, Valdyn, Kudeq, CHEMBL865, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Valdecoxib

  • Similarly, valdecoxib 5 and 10 mg/day were as effective for osteoarthritis of the hip as naproxen 500mg twice daily [1].
  • A similar reduction in hyperalgesia and allodynia was noted after twice daily administration of another COX-2 inhibitor, valdecoxib, whilst a single acute administration of either drug on day 20, produced no anti-nociceptive activity [2].
  • Valdecoxib is effective in single doses of up to 40 mg for the alleviation of acute menstrual pain and has a rapid onset of action (within 30 min) and a long duration of analgesia (up to 24 h) [3].
  • CONCLUSIONS: Preoperative orally administered valdecoxib provides well-tolerated and effective analgesia for mild to moderate postoperative pain [4].
  • RESULTS: Subjects receiving naproxen (11/60, 18%) had significantly more gastroduodenal ulcers post-treatment than those receiving placebo (2/61, 3%; P < 0.01) or valdecoxib (0/60, 0%; P < 0.001) [5].

Psychiatry related information on Valdecoxib

  • Furthermore, there were no significantly relevant differences when volunteers were treated with valdecoxib or placebo in relation to either cold- or hot pain threshold or the intensity of pain after supra-threshold, thermal pain stimulation [6].

High impact information on Valdecoxib


Chemical compound and disease context of Valdecoxib


Biological context of Valdecoxib


Anatomical context of Valdecoxib


Associations of Valdecoxib with other chemical compounds


Gene context of Valdecoxib


Analytical, diagnostic and therapeutic context of Valdecoxib


  1. Valdecoxib. Ormrod, D., Wellington, K., Wagstaff, A.J. Drugs (2002) [Pubmed]
  2. Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Fox, A., Medhurst, S., Courade, J.P., Glatt, M., Dawson, J., Urban, L., Bevan, S., Gonzalez, I. Pain (2004) [Pubmed]
  3. Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Alsalameh, S., Burian, M., Mahr, G., Woodcock, B.G., Geisslinger, G. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  4. A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Desjardins, P.J., Shu, V.S., Recker, D.P., Verburg, K.M., Woolf, C.J. Anesthesiology (2002) [Pubmed]
  5. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Goldstein, J.L., Kivitz, A.J., Verburg, K.M., Recker, D.P., Palmer, R.C., Kent, J.D. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  6. Effect of valdecoxib pretreatment on pain and secondary hyperalgesia: a randomized controlled trial in healthy volunteers [ISRCTN05282752, NCT00260325]. Burns, D., Hill, L., Essandoh, M., Jarzembowski, T.M., Schuler, H.G., Janicki, P.K. BMC anesthesiology [electronic resource]. (2006) [Pubmed]
  7. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis. Lee, C., Hunsche, E., Balshaw, R., Kong, S.X., Schnitzer, T.J. Arthritis Rheum. (2005) [Pubmed]
  8. COX-2-selective inhibitor valdecoxib induces severe allergic skin reactions. Talhari, C., Lauceviciute, I., Enderlein, E., Ruzicka, T., Homey, B. J. Allergy Clin. Immunol. (2005) [Pubmed]
  9. Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Hood, W.F., Gierse, J.K., Isakson, P.C., Kiefer, J.R., Kurumbail, R.G., Seibert, K., Monahan, J.B. Mol. Pharmacol. (2003) [Pubmed]
  10. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Birnbaum, Y., Ye, Y., Rosanio, S., Tavackoli, S., Hu, Z.Y., Schwarz, E.R., Uretsky, B.F. Cardiovasc. Res. (2005) [Pubmed]
  11. Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Edwards, J.E., McQuay, H.J., Moore, R.A. Pain (2004) [Pubmed]
  12. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. La Grenade, L., Lee, L., Weaver, J., Bonnel, R., Karwoski, C., Governale, L., Brinker, A. Drug safety : an international journal of medical toxicology and drug experience. (2005) [Pubmed]
  13. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Pavelka, K., Recker, D.P., Verburg, K.M. Rheumatology (Oxford, England) (2003) [Pubmed]
  14. Role of COX-2 inhibitors in the evolution of acute pain management. Sinatra, R. Journal of pain and symptom management. (2002) [Pubmed]
  15. Valdecoxib: a review. Chavez, M.L., DeKorte, C.J. Clinical therapeutics. (2003) [Pubmed]
  16. The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. Desjardins, P.J., Grossman, E.H., Kuss, M.E., Talwalker, S., Dhadda, S., Baum, D., Hubbard, R.C. Anesth. Analg. (2001) [Pubmed]
  17. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. Weber, A., Casini, A., Heine, A., Kuhn, D., Supuran, C.T., Scozzafava, A., Klebe, G. J. Med. Chem. (2004) [Pubmed]
  18. Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. Ibrahim, A., Park, S., Feldman, J., Karim, A., Kharasch, E.D. Anesthesiology (2002) [Pubmed]
  19. Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice. Zhang, J.Y., Yuan, J.J., Wang, Y.F., Bible, R.H., Breau, A.P. Drug Metab. Dispos. (2003) [Pubmed]
  20. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. Riendeau, D., Percival, M.D., Brideau, C., Charleson, S., Dubé, D., Ethier, D., Falgueyret, J.P., Friesen, R.W., Gordon, R., Greig, G., Guay, J., Mancini, J., Ouellet, M., Wong, E., Xu, L., Boyce, S., Visco, D., Girard, Y., Prasit, P., Zamboni, R., Rodger, I.W., Gresser, M., Ford-Hutchinson, A.W., Young, R.N., Chan, C.C. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  21. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. Kivitz, A., Eisen, G., Zhao, W.W., Bevirt, T., Recker, D.P. The Journal of family practice. (2002) [Pubmed]
  22. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Yuan, J.J., Yang, D.C., Zhang, J.Y., Bible, R., Karim, A., Findlay, J.W. Drug Metab. Dispos. (2002) [Pubmed]
  23. Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: Results of two randomized, double-blind, placebo-controlled, single-dose studies. Daniels, S.E., Desjardins, P.J., Bird, S.R., Smugar, S.S., Tershakovec, A.M. Clinical therapeutics. (2006) [Pubmed]
  24. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years. Goldstein, J.L., Aisenberg, J., Lanza, F., Schwartz, H., Sands, G.H., Berger, M.F., Pan, S. Clinical therapeutics. (2006) [Pubmed]
  25. Parecoxib (parecoxib sodium). Cheer, S.M., Goa, K.L. Drugs (2001) [Pubmed]
  26. Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial. von Scheele, B., Peña, B., Wong, J., Niculescu, L. Rheumatology (Oxford, England) (2003) [Pubmed]
  27. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. Gierse, J.K., Zhang, Y., Hood, W.F., Walker, M.C., Trigg, J.S., Maziasz, T.J., Koboldt, C.M., Muhammad, J.L., Zweifel, B.S., Masferrer, J.L., Isakson, P.C., Seibert, K. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  28. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Ibrahim, A.E., Feldman, J., Karim, A., Kharasch, E.D. Anesthesiology (2003) [Pubmed]
  29. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Walter, M.F., Jacob, R.F., Day, C.A., Dahlborg, R., Weng, Y., Mason, R.P. Atherosclerosis (2004) [Pubmed]
  30. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain. Fenton, C., Keating, G.M., Wagstaff, A.J. Drugs (2004) [Pubmed]
  31. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Eisen, G.M., Goldstein, J.L., Hanna, D.B., Rublee, D.A. Aliment. Pharmacol. Ther. (2005) [Pubmed]
WikiGenes - Universities